膀胱癌相关泌尿道及肠道微生物组学的研究进展  

Advances in urinary tract and intestinal microbiome related to bladder cancer

作　　者：齐天宇 李涛(综述)[1] 吴开杰(审校)[1] QI Tianyu;LI Tao;WU Kaijie(Department of Urology,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China)

机构地区：[1]西安交通大学第一附属医院泌尿外科,陕西西安710061

出　　处：《现代泌尿外科杂志》2023年第9期818-821,823,共5页Journal of Modern Urology

基　　金：国家自然科学基金项目(No.81572516);白求恩·泌尿肿瘤专项研究基金项目(No.mnzl202010)。

摘　　要：膀胱癌是最常见的泌尿系肿瘤之一,而人体泌尿道已被证明并非无菌,泌尿道菌群在尿路上皮癌的病理生理学和治疗中的意义尚有待研究。同时肠道菌群也已成为临床上的重要因素,被证明在机体新陈代谢、局部和全身炎症以及免疫中有各种作用,微生物能影响癌症的临床进程、化疗或免疫治疗药物的疗效、生物利用度和副作用。本综述将探讨膀胱癌与泌尿道、肠道微生物之间的关系,通过对微生物组与肿瘤细胞之间相互作用的更好理解,挖掘可靠的疾病预测因子、预后指标以及治疗靶点。Bladder cancer is one of the most common urinary tumors,and human urinary tract has been proved to be non-sterile.The significance of urinary tract flora in pathophysiology and treatment of urothelial carcinoma remains to be studied.Meanwhile,intestinal flora has also become an important clinical factor,which has been proved to play a variety of roles in body metabolism,local and systemic inflammation and immunity.Microorganisms can affect the clinical course of cancer,efficacy of chemotherapy and immunotherapy drugs,bioavailability and side effects.This review will explore the relationship between bladder cancer and urinary tract and intestinal microbiome,and explore reliable disease predictors,prognostic indicators and therapeutic targets through a better understanding of the interaction between the microbiome and tumor cells.

关 键 词：膀胱癌 微生物组学 泌尿道菌群 肠道菌群 肿瘤免疫治疗 

分 类 号：R737.14[医药卫生—肿瘤]